Barrick Mining Corporation Stock Price, News & Analysis

BioArctic AB (Nasdaq Stockholm: BIOA B) announced that its partner Eisai has received approval from China's NMPA for Leqembi's (lecanemab) IV maintenance treatment in early Alzheimer's disease. The new approval allows for a maintenance dosing regimen of 10 mg/kg once every four weeks after an 18-month initiation phase of bi-weekly dosing.

Leqembi, initially approved in China in January 2024, is notable as the only approved therapy targeting both amyloid plaque and protofibrils in Alzheimer's disease treatment. The drug was developed through a collaboration between BioArctic and Eisai, based on Professor Lars Lannfelt's research on the Arctic mutation in Alzheimer's disease.

BioArctic AB (Nasdaq Stockholm: BIOA B) announced that Australia's Therapeutic Goods Administration (TGA) has approved Leqembi (lecanemab) for treating early Alzheimer's disease. The approval specifically targets adult patients with mild cognitive impairment or mild dementia who are apolipoprotein E ε4 non-carriers or heterozygotes with confirmed amyloid pathology.

This approval follows a review process initiated in March 2025 after an initial rejection in February 2025. Leqembi, developed through collaboration between BioArctic and Eisai, originated from Professor Lars Lannfelt's research on the Arctic mutation in Alzheimer's disease. While Eisai leads global commercialization, BioArctic maintains Nordic region commercialization rights in partnership with Eisai.

Hexagon US Federal, the federal arm of Hexagon, has confirmed its commitment to supporting national security missions amid organizational changes. The company addressed its strategic position following Hexagon's planned spin-off of Octave, expected in early 2026. The spin-off will include Safety, Infrastructure & Geospatial and Asset Lifecycle Intelligence divisions, along with Bricsys and ETQ units.

Hexagon US Federal will maintain a unique dual alignment, supporting both Octave's portfolio and Hexagon's continuing operations. This position enables the company to accelerate growth in SaaS offerings for public safety and geospatial intelligence while supporting established technologies like Leica Geosystems and Position, Navigation and Timing solutions.

Barrick Mining (NYSE:B) has announced that its Fourmile project in Nevada is emerging as one of the century's most significant gold discoveries. The updated preliminary economic assessment (PEA) reveals potential for annual gold production of 600-750,000 ounces at mining rates of 1.5-1.8Mt per year.

The project boasts exceptional characteristics including high-grade resources of 3.6Mt @ 11.8g/t for 1.4Moz (M&I) and 14Mt @ 14.1g/t for 6.4Moz (Inferred), with exploration upside potential of 32-34Mt @ 15-16g/t. The project's preliminary economics indicate a mine life exceeding 25 years with projected AISC of $650-750/oz and estimated project capital of $1.5-1.7 billion.

Barrick Mining (NYSE:B) has announced the sale of its Hemlo Gold Mine in Canada to Carcetti Capital Corp. (to be renamed Hemlo Mining Corp.) for up to $1.09 billion. The deal structure includes $875 million in cash, $50 million in HMC shares, and potential additional payments of up to $165 million linked to production and gold prices starting January 2027.

HMC is led by experienced mining executive Robert Quartermain and backed by Wheaton Precious Metals and Orion Mine Finance Management. The transaction, expected to close in Q4 2025, is part of Barrick's strategy to focus on its Tier One gold and copper portfolio, with total proceeds from non-core asset sales expected to exceed $2 billion this year.

BioArctic (NASDAQ STOCKHOLM: BIOA B) announced that CEO Gunilla Osswald has been named Uppsala University's Alumnus of the Year 2025. The recognition highlights her exemplary leadership and contributions to scientific innovation, particularly in the development of lecanemab for Alzheimer's disease.

Earlier in March 2025, Osswald and BioArctic's founders were also awarded the university's Innovation and Entrepreneurship Prize. The university praised her visionary and inclusive leadership style, noting her ability to foster collaboration and serve as a role model for women in science and technology.

Integrum AB (INTEG B) unveiled its new global marketing strategy at the AOPA National Assembly in Orlando, introducing BondedMatrix™, a term describing the OPRA™ Implant System's unique capability to integrate soft tissue and bone. The strategy aims to better communicate the system's distinct advantages in bone-anchored prosthetics.

The OPRA™ Implant System, invented by Dr. Rickard Brånemark, has been refined since 1990 and has been used in over 1,000 implants worldwide. BondedMatrix™ specifically refers to the biologically integrated barrier connecting skin and bone at the penetration site, a unique feature achieved through OPRA's surgical technique and implant design.

BioArctic AB (Nasdaq Stockholm: BIOA B) announced that its partner Eisai has initiated a rolling submission of a Supplemental Biologics License Application (sBLA) to the FDA for Leqembi Iqlik's subcutaneous autoinjector as a weekly starting dose for early Alzheimer's disease treatment. This follows the recent approval of Leqembi Iqlik for maintenance dosing in the US on August 29, 2025.

If approved, Leqembi Iqlik would become the first anti-amyloid treatment offering at-home injection from start to maintenance. The proposed dosing regimen includes 500 mg SC dosing (two 250 mg injections) weekly, as an alternative to bi-weekly intravenous dosing. The autoinjector requires only 15 seconds per injection and could potentially reduce healthcare resources associated with IV administration.

Leqembi, currently approved in 48 countries and under review in 10 others, uniquely targets both amyloid plaque and protofibrils in Alzheimer's disease treatment.

Integrum AB (Nasdaq First North: INTEG B) has scheduled its first quarter 2025/26 results presentation for September 1, 2025, at 10:00 CET. The presentation will be conducted via webcast, featuring CEO Martin Hillsten and CFO Jörgen Svanström presenting the quarterly report in English.

The report and presentation materials will be accessible through the company's investor relations website and the Finwire.tv platform, where participants will have the opportunity to ask questions during the session.